NVSEF - Novartis AG
| Previous Close | 98.04 |
| Open | 98.04 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 98.04 - 98.04 |
| 52 Week Range | 72.98 - 106.50 |
| Volume | |
| Avg. Volume | 57,588 |
| Market Cap | 207.807B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 30.07 |
| EPS (TTM) | 3.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.43 (3.48%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
ZacksKodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
ZacksAre Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
ZacksNovo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
ZacksBristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
ZacksTime to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
ZacksAlimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
GlobeNewswireSandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-
ZacksNovo Nordisk (NVO) Collaborates for Gene-Editing Therapies
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
ZacksZacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
ZacksNovo Nordisk (NVO) Announces Positive Obesity Program Data
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
ZacksInvest in These Dividend Growth Stocks Amid Default Fears
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
ZacksAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
ZacksNovartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
ZacksWhy Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Simply Wall St.Is Novartis AG's (VTX:NOVN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...
ZacksRoche's (RHHBY) MS Drug Meets Goals in the Phase II Study
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
ZacksBayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
ZacksEli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
GlobeNewswireNew Sandoz Board of Directors appointed
Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2 2023 Experienced and diverse group of corporate leaders with a track record of growing businesses and driving value for the organization and society will help set strategic direction for Sandoz and support its future development Basel, May 15, 2023 — Sandoz takes the next steps to prepare for the pl
- Zacks
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
- GlobeNewswire
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial reaffirm Scemblix superiority over Bosulif* in patients with chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors Preliminary global results from large-scale Survey on Unmet Needs in CML disrupt notion that CML is solved and underscore import
Yahoo FinanceNovartis CEO criticizes US, EU efforts to curb drug company power
Novartis CEO pushes back against government attempts to direct pharma R&D
ZacksWhat Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksIs Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
